Leishmania donovani Exploits Myeloid Cell Leukemia 1 (MCL-1) Protein to Prevent Mitochondria-dependent Host Cell Apoptosis

J Biol Chem. 2016 Feb 12;291(7):3496-507. doi: 10.1074/jbc.M115.672873. Epub 2015 Dec 15.

Abstract

Apoptosis is one of the mechanisms used by host cells to remove unwanted intracellular organisms, and often found to be subverted by pathogens through use of host anti-apoptotic proteins. In the present study, with the help of in vitro and in vivo approaches, we documented that the macrophage anti-apoptotic protein myeloid cell leukemia 1 (MCL-1) is exploited by the intra-macrophage parasite Leishmania donovani to protect their "home" from actinomycin D-induced mitochondria-dependent apoptosis. Among all the anti-apoptotic BCL-2 family members, infection preferentially up-regulated expression of MCL-1 at both the mRNA and protein levels and compared with infected control, MCL-1-silenced infected macrophages documented enhanced caspase activity and increased apoptosis when subjected to actinomycin D treatment. Phosphorylation kinetics and ChIP assay demonstrated that infection-induced MCL-1 expression was regulated by transcription factor CREB (cAMP-response element-binding protein) and silencing of CREB resulted in reduced expression of MCL-1 and increased apoptosis. During infection, MCL-1 was found to be localized in mitochondria and this was significantly reduced in Tom70-silenced macrophages, suggesting the active role of TOM70 in MCL-1 transport. In the mitochondria, MCL-1 interacts with the major pro-apoptotic protein BAK and prevents BAK-BAK homo-oligomer formation thereby preventing cytochrome c release-mediated mitochondrial dysfunction. Silencing of MCL-1 in the spleen of infected mice showed decreased parasite burden and increased induction of splenocyte apoptosis. Collectively our results showed that L. donovani exploited the macrophage anti-apoptotic protein MCL-1 to prevent BAK-mediated mitochondria-dependent apoptosis thereby protecting its niche, which is essential for disease progression.

Keywords: B-cell lymphoma 2 (Bcl-2) family; Leishmania; apoptosis; cytochrome c; macrophage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparasitic Agents / pharmacology*
  • Antiparasitic Agents / therapeutic use
  • Apoptosis / drug effects*
  • Bone Marrow Cells / drug effects
  • Bone Marrow Cells / metabolism
  • Bone Marrow Cells / parasitology
  • Bone Marrow Cells / pathology
  • Cells, Cultured
  • Cyclic AMP Response Element-Binding Protein / antagonists & inhibitors
  • Cyclic AMP Response Element-Binding Protein / genetics
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Dactinomycin / pharmacology
  • Dactinomycin / therapeutic use
  • Female
  • Gene Expression Regulation / drug effects
  • Host-Parasite Interactions / drug effects*
  • Leishmania donovani / drug effects*
  • Leishmania donovani / growth & development
  • Leishmania donovani / physiology
  • Leishmaniasis, Visceral / drug therapy*
  • Leishmaniasis, Visceral / metabolism
  • Leishmaniasis, Visceral / parasitology
  • Leishmaniasis, Visceral / pathology
  • Macrophages / drug effects*
  • Macrophages / metabolism
  • Macrophages / parasitology
  • Macrophages / pathology
  • Mice
  • Mice, Inbred BALB C
  • Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors
  • Myeloid Cell Leukemia Sequence 1 Protein / genetics
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism*
  • Phosphorylation / drug effects
  • Protein Processing, Post-Translational / drug effects
  • Protein Transport / drug effects
  • RAW 264.7 Cells
  • RNA Interference
  • Spleen / drug effects
  • Spleen / metabolism
  • Spleen / parasitology
  • Spleen / pathology

Substances

  • Antiparasitic Agents
  • Creb1 protein, mouse
  • Cyclic AMP Response Element-Binding Protein
  • Mcl1 protein, mouse
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Dactinomycin